Voriconazole use for endemic fungal infections.

Abstract

In a retrospective review of 24 patients with histoplasmosis, blastomycosis, or coccidioidomycosis treated with voriconazole (most for salvage therapy), the outcome was favorable (improved or stable) for 22 (95.8%) within 2 months of starting voriconazole and for 20 (83.3%) at the last follow-up. Prospective studies are required to determine its role in the treatment of endemic mycoses.

• Authors: Alison Freifeld, Laurie Proia, David Andes, Larry M Baddour, Janis Blair, Brad Spellberg, Sandra Arnold, Arnold Lentnek, L Joseph Wheat
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 53 Issue 4 Pg. 1648-51 (Apr 2009) ISSN: 1098-6596 [Electronic] United States
• PMID: 19139290 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antifungal Agents
• Pyrimidines
• Triazoles
• Voriconazole

Topics

• Adolescent
• Adult
• Aged
• Antifungal Agents (therapeutic use)
• Blastomycosis (drug therapy)
• Coccidioidomycosis (drug therapy)
• Female
• Histoplasmosis (drug therapy)
• Humans
• Male
• Middle Aged
• Pyrimidines (therapeutic use)
• Retrospective Studies
• Triazoles (therapeutic use)
• Voriconazole